How long does gene therapy last? 4-year follow-up of phase 3 voretigene neparvovec trial in RPE65-associated LCA/inherited retinal disease

Author(s):  
Arlene V. Drack ◽  
Jean Bennett ◽  
Stephen Russell ◽  
Katherine A. High ◽  
Zi-fan Yu ◽  
...  
2021 ◽  
Vol 39 (4) ◽  
pp. 383-397
Author(s):  
Simone A. Huygens ◽  
Matthijs M. Versteegh ◽  
Stefan Vegter ◽  
L. Jan Schouten ◽  
Tim A. Kanters

2021 ◽  
Vol 61 (4) ◽  
pp. 3-45
Author(s):  
Aumer Shughoury ◽  
Thomas A. Ciulla ◽  
Benjamin Bakall ◽  
Mark E. Pennesi ◽  
Szilárd Kiss ◽  
...  

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Jason Charng ◽  
Di Xiao ◽  
Maryam Mehdizadeh ◽  
Mary S. Attia ◽  
Sukanya Arunachalam ◽  
...  

Abstract Stargardt disease is one of the most common forms of inherited retinal disease and leads to permanent vision loss. A diagnostic feature of the disease is retinal flecks, which appear hyperautofluorescent in fundus autofluorescence (FAF) imaging. The size and number of these flecks increase with disease progression. Manual segmentation of flecks allows monitoring of disease, but is time-consuming. Herein, we have developed and validated a deep learning approach for segmenting these Stargardt flecks (1750 training and 100 validation FAF patches from 37 eyes with Stargardt disease). Testing was done in 10 separate Stargardt FAF images and we observed a good overall agreement between manual and deep learning in both fleck count and fleck area. Longitudinal data were available in both eyes from 6 patients (average total follow-up time 4.2 years), with both manual and deep learning segmentation performed on all (n = 82) images. Both methods detected a similar upward trend in fleck number and area over time. In conclusion, we demonstrated the feasibility of utilizing deep learning to segment and quantify FAF lesions, laying the foundation for future studies using fleck parameters as a trial endpoint.


Author(s):  
Arlene V. Drack ◽  
Jean Bennett ◽  
Stephen Russell ◽  
Jennifer A. Wellman ◽  
Daniel C. Chung ◽  
...  

Ophthalmology ◽  
2021 ◽  
Author(s):  
Albert M. Maguire ◽  
Stephen Russell ◽  
Daniel C. Chung ◽  
Zi-Fan Yu ◽  
Amy Tillman ◽  
...  

Author(s):  
Matthew P. Simunovic ◽  
Heather G. Mack ◽  
Lauren N. Ayton ◽  
Mark M. Hassall

2019 ◽  
Vol 36 (2) ◽  
Author(s):  
Tuyen Ong ◽  
Mark E. Pennesi ◽  
David G. Birch ◽  
Byron L. Lam ◽  
Stephen H. Tsang

Genes ◽  
2019 ◽  
Vol 10 (10) ◽  
pp. 738 ◽  
Author(s):  
Jasmina Cehajic Kapetanovic ◽  
Alun R. Barnard ◽  
Robert E. MacLaren

Advances in molecular research have culminated in the development of novel gene-based therapies for inherited retinal diseases. We have recently witnessed several groundbreaking clinical studies that ultimately led to approval of Luxturna, the first gene therapy for an inherited retinal disease. In parallel, international research community has been engaged in conducting gene therapy trials for another more common inherited retinal disease known as choroideremia and with phase III clinical trials now underway, approval of this therapy is poised to follow suit. This chapter discusses new insights into clinical phenotyping and molecular genetic testing in choroideremia with review of molecular mechanisms implicated in its pathogenesis. We provide an update on current gene therapy trials and discuss potential inclusion of female carries in future clinical studies. Alternative molecular therapies are discussed including suitability of CRISPR gene editing, small molecule nonsense suppression therapy and vision restoration strategies in late stage choroideremia.


Sign in / Sign up

Export Citation Format

Share Document